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Background: Allergic rhinitis has been suspected to be a risk factor for asthma in several studies
but this association is not firmly established. The objective of this study was to synthesize the
evidence of the association between allergic rhinitis and the risk of asthma through a systematic
review and meta-analysis.
Methods: We performed a search in Medline, Scopus, ISI Proceedings databases and other
databases from inception until February 2019, followed by manual search to identify potentially
relevant case-control and cohort studies that reported relative risk estimates and confidence in-
tervals of the association between allergic rhinitis and asthma. Cross-sectional studies were
excluded. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed
and random effects models and quality of studies was assessed through a modified version of the
Newcastle-Ottawa scale.
Results: Twenty-nine eligible studies, 22 cohort and 7 case-control studies, with a total of 274489
subjects, were included in the meta-analysis. The results show that history of allergic rhinitis is
significantly associated with the occurrence of asthma (OR ¼ 3.82; 95% CI: 2.92–4.99). European
studies showed a stronger association (OR ¼ 4.35; (95% CI: 3.12–6.06) than non-European studies
(OR ¼ 2.75; 95% CI: 2.16–3.50), and case-control studies showed a stronger association
(OR ¼ 4.71; 95% CI: 3.58–6.17) than cohort studies (OR ¼ 3.42; 95% CI: 2.60–4.50).
Conclusions: This meta-analysis shows that allergic rhinitis is strongly associated with asthma.
Further prospective studies on the effect of treatment of allergic rhinitis on the development of
asthma are needed. Relief of airway allergic manifestations may need dual control of allergic
rhinitis and asthma.
Registration: PROSPERO database with registration number CRD42017055156.
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Asthma is an important health problem. Its
prevalence is increasing worldwide, especially in
low and middle income countries.1 The Global
Burden of Disease 2015 estimated that nearly
400 million people around the world suffer from
this condition. Asthma is considered as the 11th
highest cause of Years Lived with Disability
(YLDs) worldwide.2,3
Allergic Rhinitis (AR) is a disease the prevalence
of which is increasing in a similar fashion to that of
asthma.1 It affects 10–30% of the general
population and is suspected to be a risk factor
for onset of asthma in several epidemiologic
studies.4–7 However, most studies of this relation
are of a cross-sectional nature, a design that
could prove inadequate for causal inference.
Furthermore, the remaining case-control and
cohort studies evaluating this association show
effect estimates the magnitude of which vary
considerably from study to study, swaying be-
tween absence of statistically significant associa-
tion,8 and extremely strong relationships.9 Yet in
2012, the ARIA (Allergic Rhinitis and its Impact
on Asthma) guidelines stated that sophisticated
statistical methods should be implemented in
order to have a more objective view of the link
between AR and asthma.10
To provide a global assessment and a quanti-
tative summary of the association between AR and
asthma, we performed a systematic review and
meta-analysis of cohort and case-control studies.METHODS
Search strategy
We searched MEDLINE via Pubmed, Scopus,
the Conference Proceedings Citation Index-
Science (CPCI–S) database, the Open Access
Theses and Dissertations (OATD), and the 5
regional bibliographic databases of the World
Health Organization (WHO) (African Index Medi-
cus, Latin American and Caribbean Health Science
Literature Database, Index Medicus for the Eastern
Mediterranean Region, Index Medicus for South-
East Asia Region, Western Pacific Region Index
Medicus), from inception of each database to theend of February 2019, without any language limi-
tation. The search strategy was as follows:
((((("Rhinitis, Allergic, Seasonal"[Mesh]) OR
("Rhinitis, Allergic"[Mesh]) OR "allergic rhinitis" OR
rhinitis)))) AND (("Asthma"[Mesh]) OR asthma) AND
(((("Case-Control Studies"[Mesh]) OR "Cohort
Studies"[Mesh]) OR case-control) OR cohort) for
Medline and equivalent wording in other data-
bases. Due to the nature of exposure, rhinitis, our
meta-analysis had to be based on observational
studies only, in spite of their limitations. No
experimental studies can be carried out on this
topic. To find any additional published study, the
reference lists of all retrieved articles and related
review articles were searched manually. All
searches were performed by two independent
reviewers (HRT and NM) and disagreements about
inclusion of some studies were resolved by
consensus and, when needed, by consulting with a
third party (BT). The review protocol was registered
in PROSPERO with registration number
CRD42017055156.
Inclusion criteria
Case-control and cohort studies were included
if: 1) the main or secondary outcome was asthma,
2) the exposure of interest or one of the covariates
was allergic rhinitis, 3) they reported a measure of
association between allergic rhinitis and asthma
such as Risk Ratio, Rate Ratio, Odds Ratio and their
variance, standard error or 95% confidence in-
tervals (CI), or provided enough raw data to
calculate them.Whenever necessary, we contacted
the authors to provide more information for the
calculation of the effect measure or to clarify some
methodologic aspects of the study.11–14 Studies
without comparison group (allergic rhinitis-free in
cohort studies and asthma-free in case-control
studies) and those that did not report measures
of effect nor provide enough information for
calculating them were excluded.13 If a study did
not adjust for any factor, this study was not
excluded but instead, we used its crude
estimate.8,15 In case of duplication of a
publication, we included the most complete one.
When we were unable to assess whether two
publications were from the same study, we
contacted their authors to consult about this
issue.7,16–21
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Data were extracted using a predefined form
with the following information: first author, year of
publication, country, study design, source of data,
type of population, number of participants, mean
age of participants, measure of association, and
adjustment, restriction or matching factors. The
data were extracted following the same procedure
as that used for the bibliographic searches. The
extraction was carried out independently by 2 au-
thors and discrepancies were resolved by
consensus.Quality assessment
We assessed the quality of the studies using a
modified version of the Newcastle-Ottawa scale
that we adapted to the needs of this meta-analysis.
We used a common quality assessment form for
both case-control and cohort studies to be able to
use their score in a comprehensive fashion.We first
performed an analysis based on the global score
and then subsequent analyses based on each cri-
terion. The following 5 criteria were considered on
a yes/no basis: 1) whether the target population
was clearly defined or just based on convenience
sampling, 2) whether asthma diagnosis is based on
clinical features and spirometry (flow rate) and/or
reversal after treatment or was only based on
clinical examination, 3) whether rhinitis diagnosis is
based on clinical and lab examination or was
based on questionnaire only, 4) whether or not
asthma symptoms clearly occurred after rhinitis
onset, and 5) whether or not results were adjusted
for age, sex and family history of asthma. Each item
was scored as 0 or 1. Quality assessment was
independently conducted by two investigators
(HRT and NM) and disagreements were solved by
a third investigator (BT).Statistical methods
Risk Ratios and Rate Ratios in cohort studies and
Odds Ratios in case control studies were consid-
ered as measures of effect in this meta-analysis.
Odds Ratios from case-control studies were
assumed to be unbiased estimates of the Rate
Ratios.22 Heterogeneity among studies was
evaluated via the Ri statistic (the proportion of
total variance due to between-studies variance)23as well as the DerSimonian & Laird Q test, in
which a p-value<0.1 was considered as
statistically significant. For pooling the effect size
estimates, the inverse of variance was considered
as the weight for each study. We computed both
fixed effects and random effects estimates, but as
heterogeneity was frequent in subgroup analyses,
we presented random effects data only. For each
study we used the estimate that was adjusted for
the largest number of variables.
We performed subgroup analysis according to
the design of studies, region, age group, quality
score, and items of quality assessment. Cumulative
meta-analysis was conducted to identify any trend
in estimates across time. The Begg’s rank correla-
tion test and the Egger regression test were used
to statistically assess publication bias. We also
visually assessed publication bias using a funnel
plot and performed the Trim-and-Fill procedure to
estimate the number of potential missing studies in
our meta-analysis and their effect on the
outcome.24 HEpiMA software25 and STATA 12
(Stata Corp, College Station, TX, USA) were used
for statistical analysis.RESULTS
We found a total of 29 eligible studies, including
22 cohort studies and 7 case-control studies with a
total of 274,489 subjects.6–9,11,12,15,16,26–45
Twenty one studies were conducted in Euro-
pean countries and 8 in non-European countries
between 1994 and 2019. Except for 2 articles
published in Spanish44 and German,9 the rest
were written in English. One article comprised 2
independent case-control studies carried out in
different countries. We, therefore, considered
these 2 studies separately.45 Among the studies
that could have been potentially included in our
meta-analysis, we excluded 3 articles17–19
because of overlap of data with a more
comprehensive study.7 Furthermore, we found 3
articles from the same author,16,20,21 2 of which
were excluded after consulting with the
author.20,21 We also excluded 1 conference
abstract,46 as after contacting the authors, we
were informed that the corresponding study was
published later as a full paper in another
language.9 One study was excluded as we could
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Volume 12, No. 10, October 2019 9not trace its authors to collect the necessary
information to calculate effect measures.13 Data
from 2 studies were obtained through contact
with the authors.11,12 We did not find any
relevant study published in a book or
dissertation. The main characteristics of the
remaining 29 studies included in this meta-
analysis are summarized in Tables 1 and 2. The
flow diagram presenting the screening process
and the reasons for exclusion is presented in
Fig. 147
Association of allergic rhinitis and asthma
After pooling the data using the random effect
model, we observed that history of allergic rhinitis
is strongly associated with asthma (pooled Odds
Ratio ¼ 3.82; 95% CI: 2.92–4.99). Subgroup anal-
ysis showed that this association was weaker for
non European studies (OR ¼ 2.75; 95% CI: 2.16–
3.50) than for European studies (OR ¼ 4.35; 95%
CI: 3.12–6.06). Although the association was sig-
nificant in both designs, case-control studies
showed a stronger association (OR ¼ 4.71; 95%
CI: 3.58–6.17) than cohort studies (OR ¼ 3.42;
95% CI: 2.60–4.50). The association was similar in
studies with low and high quality scores
(OR ¼ 3.86; 95% CI: 2.49–6.00 versus 3.61; 95%
CI: 2.97–4.39, respectively), while studies on chil-
dren showed a stronger relation (OR ¼ 4.10; 95%
CI: 2.56–6.56) than those conducted on adults
(OR ¼ 3.37; 95% CI: 2.64–4.30). The detailed in-
formation as well as results of other subgroup
analyses are presented in Table 3. In all analyses
(overall and subgroups) there was evidence of
heterogeneity between studies (Table 3, Fig. 2).
Based on the proportion of total variance due to
between-study variance, this heterogeneity was
low for studies with full adjustment and moderate
for the following subgroups: case-control studies,
good quality studies, non-European studies and
studies with adequate diagnosis of asthma and
rhinitis, while this heterogeneity was high for the
rest of subgroups.
Publication bias
The funnel plot of effect size of the studies was
slightly skewed to the right (Fig. 3), and the Begg’s
test (p-value ¼ 0.023) provided some evidence for
the presence of small-study effects. However, the
Egger’s test showed no evidence of publication
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730 in ISI proceedings, 3065 in 
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Fig. 1 Flow diagram of study selection in systematic review and meta-analysis of history of allergic rhinitis and risk of asthma
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http://doi.org/10.1016/j.waojou.2019.100069bias (p-value ¼ 0.66). The Trim-and-Fill procedure
did not impute any study when we applied the
random effects model, while one study was
imputed when the fixed effects model was used.
The pooled OR after inclusion of this study was
3.67 (95% CI: 3.56–3.78), very close to the original
pooled OR of 3.82 (95% CI: 2.92–4.99).
To evaluate the possibility of publication bias in
case–control studies, the design most susceptible
to be rejected by journals when results lack sta-
tistical signification, we recalculated our pooled
estimates under the following extreme assump-
tions: 1) published studies listed in Table 2 are
only half of the case-control studies on allergic
rhinitis and risk of asthma ever conducted, 2) all
studies of the unpublished half found null associ-
ations (ie, OR ¼ 1) between allergic rhinitis and
asthma, and 3) on average, the unpublished
studies included as many cases and controls as thepublished ones. Under these assumptions, the
observed pooled OR was 2.89 (95% CI: 2.19–3.81)
that was still large enough to support the findings
of our study.
We performed another simulation to evaluate
the robustness of our results to the publication
bias. We calculated how many unpublished nega-
tive (OR ¼ 1) case-control studies with as many
cases and controls as the average number of the
published studies were necessary to reverse our
conclusions. Our simulation showed that 187
negative studies were needed to obtain a pooled
OR of 1.10 (95% CI: 1.06–1.14) and 945 studies to
obtain an OR of 1.01 (95% CI: 1.003–1.018).Cumulative meta-analysis
Cumulative meta-analysis by year of publication
showed that the first stable and statistically
Groups Number of studies OR (95% CI) Ria p- value of Q test
All studies 29 3.82 (2.92–4.99) 0.98 <0.001
Design
Cohort studies 22 3.42 (2.60–4.50) 0.96 <0.001
Case-control studies 7 4.71 (3.58–6.17) 0.70 0.003
Region
European 21 4.35 (3.12–6.06) 0.98 <0.001
Non European 8 2.75 (2.16–3.50) 0.73 <0.001
Age group
Children 15 4.10 (2.56–6.56) 0.99 <0.001
Adults 14 3.37 (2.64–4.30) 0.89 <0.001
Quality Score
<3 11 3.86 (2.49–6.00) 0.99 <0.001
3 18 3.61 (2.97–4.39) 0.51 0.006
Items of quality assessment:
Proper definition of target population
Yes 23 3.42 (2.62–4.48) 0.96 <0.001
No 6 6.26 (3.18–12.30) 0.97 <0.001
Proper diagnosis of asthma
Yes 9 3.67 (2.52–5.34) 0.81 <0.001
No 20 3.82 (2.92–4.99) 0.98 <0.001
Proper diagnosis of Allergic Rhinitis
Yes 12 5.06 (3.58–7.15) 0.64 0.001
No 17 3.18 (2.26–4.46) 0.99 <0.001
Clear temporal trend between rhinitis
and occurrence of asthma
Yes 24 3.55 (2.74–4.61) 0.96 <0.001
No 5 4.89 (3.26–7.35) 0.68 0.015
Adjustment
Full adjustment 12 3.82 (2.92–4.98) 0.43 0.057
Incomplete adjustment 17 3.94 (2.77–5.61) 0.99 <0.001
























































































































































Fig. 2 Forest plot of the association between history of allergic rhinitis and risk of asthma (random effects)
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http://doi.org/10.1016/j.waojou.2019.100069significant effect was observed after including the
study by Huovinen et al. published in 1999 (pooled
OR ¼ 2.19; 95% CI: 1.19–4.04).39 The pooled OR
increased up to a value of 3.46 (95% CI: 1.62–
7.39) after adding the study of Linneberg et al.,
in 2002,11 but subsequent studies did not
change the strength of association in a
meaningful fashion and just increased the
precision of the pooled estimate (Fig. 4).DISCUSSION
Our meta-analysis showed that allergic rhinitis is
associated with the occurrence of asthma. This
association was observed in all subgroups, albeit
with different magnitudes. A plausible explanation
of this association is provided by the “atopic
march” hypothesis that considers atopic disorders
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Fig. 3 Funnel plot of association between history of allergic rhinitis
and risk of asthma
Volume 12, No. 10, October 2019 13which start with atopic dermatitis, follow with
allergic rhinitis, and end up with asthma as sensi-
tizations in upper and lower airways, respec-
tively.48 A similar view is represented by the “one
airway, one disease” concept, in which AR and
asthma are believed to be but one unique
disease.49
In a study in human subjects, Braunstahl et al.
revealed that the provocation of nasal mucosa with
allergens results in an increase in lower airways
eosinophilia in patients with AR.50 In addition, the
increase in the risk of asthma after exposure to AR
is supported by some experimental animal studies.
Li et al. showed that exposure of nasal mucosa to
allergens increases the concentration of factors
that are related to asthma such as eosinophils,
interleukin-5 and CD34 cells in peripheral blood
and bone marrow in mice.51
Another explanation of the relation of allergic
rhinitis and asthma could be represented by the
existence of a common cause for these two dis-
eases, which affects upper and lower airways in
different periods and could play a role of
confounder in this association. Some studies
showed that polymorphisms in the filaggrin gene,
such as R501X and 2282del4, are related to both
AR and asthma.52,53 Also, inhalant allergens, such
as pollen, pets, house dust mites, and moulds
could be predictors of AR and asthma.
Nevertheless, the existence of a strong
confounder that could explain the total of theassociation observed is unlikely. Even if this
unidentified factor (either a polymorphism or an
environmental factor) could multiply by 5 the risk
of asthma among subjects exposed to it (Relative
Risk confounder–disease ¼ 5) and, at the same
time, this factor is 5 times more prevalent among
people suffering from AR than among the rest of
the population (Relative Risk confounder–
exposure ¼ 5), the adjusted Relative Risk of the
relation rhinitis-asthma would still be 2.30
(assuming one-third of people are exposed to this
unknown factor).54 The existence of a factor so
strongly associated with rhinitis on one side, and
with asthma on the other side, is highly
improbable.
This meta-analysis showed a large amount of
heterogeneity that persisted after stratification in
subgroups. We therefore focused our interpreta-
tion on the random effects estimates as recom-
mended.55,56 Meta-analysis experts claim that
there is no amount of heterogeneity that is unac-
ceptable provided the eligibility criteria are sound
and the data are correct,55 and that heterogeneity
in meta-analysis, due to the differences in methods
and populations, should be viewed as the
“expectation, rather than the exception”.57
Publication bias is unlikely to happen in this
meta-analysis because the association remained
strong even after extremely conservative assump-
tions about the potentially related but unpublished
studies. In addition, although the Begg’s test
showed some evidence of publication bias,
Egger’s test did not confirm it and the Trim-and-Fill
procedure did not modify the results obtained
previously. Furthermore, to prevent this bias, we
conducted a thorough electronic and manual
search, without any language restriction, in virtually
every available database that could provide arti-
cles, dissertations, and conference abstracts.
Furthermore, the results observed do not
depend on the intrinsic quality of the studies as the
magnitude of the association is similar among
studies deemed to be of high quality and studies
with a lower quality score.
To the best of our knowledge, this study is the
first meta-analysis on this topic. However, there are






























































































Fig. 4 Cumulative forest plot of the association between history of allergic rhinitis and risk of asthma
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http://doi.org/10.1016/j.waojou.2019.100069retrieved all related studies or which have included
cross sectional studies, a type of studies which
cannot provide reliable evidence for cause-effect
relationship due to its inability to assess a tempo-
ral trend between the occurrence of AR and that of
asthma. To avoid this bias, our meta-analysis
excluded cross-sectional designs and used
cohort and case-control studies only.In conclusion, the magnitude of the associa-
tions, and the consistency of the results in different
settings provide strong epidemiological evidence
that people with allergic rhinitis have a higher
odds of asthma occurrence than healthy people.
Further prospective studies on the effect of treat-
ment of allergic rhinitis on the development of
asthma are needed. Relief of airway allergic
Volume 12, No. 10, October 2019 15manifestations may need dual control of allergic
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